A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas

Inclusion criteria

• . Patients meeting any of the conditions a) to c) below:
• . Have a diagnosis of diffuse intrinsic pontine glioma on the basis of imaging findings on magnetic resonance imaging (MRI) and clinical course
• . Have histologically or cytologically confirmed glioblastoma
• . Not meeting a) and b) above, but have histologically or cytologically confirmed grade III or IV glioma
• . Patients who will be able to be hospitalized from the initial dose of DSP-7888 until the end of the post-initial dose observation (In Phase 1 part only, patients may be permitted to have a temporary overnight leave during the hospitalization.)
• . Patients aged \< 20 years at the time of informed consent
• . Patients for whom either the legally acceptable representative or the patient (if aged ≥ 16 years) have provided written voluntary consent to participation in this study after fully receiving and understanding the information about this study, including study objectives, contents, expected pharmacological actions and effects, and foreseeable risks
• . Patients for whom standard therapy failed or no standard therapy is established

Exclusion criteria